Tetraphase Receives a Hold from BMO Capital

By Carrie Williams

BMO Capital analyst Ian Somaiya reiterated a Hold rating on Tetraphase (NASDAQ: TTPH) yesterday and set a price target of $6. The company’s shares opened today at $3.11, equals to its 52-week low of $3.11.

According to TipRanks.com, Somaiya is a 5-star analyst with an average return of 8.9% and a 44.0% success rate. Somaiya covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Corcept Therapeutics Inc., and Protagonist Therapeutics.

Tetraphase has an analyst consensus of Hold, with a price target consensus of $6.

The company has a one year high of $12.45 and a one year low of $3.11. Currently, Tetraphase has an average volume of 340K.

Tetraphase Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of tetracycline antibiotics. Its portfolio includes Eravacycline, TP-271, and TP-6076. These products targets the treatment of urinary tract infections and community-acquired bacterial pneumonia. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.